A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin followed by Lenalidomide (GROC-Rev)

No optimal salvage therapy for relapsed/refractory aggressive histological types of non-Hodgkin lymphoma exists. We explored a combination of single-agent lenalidomide following gemcitabine, rituximab, oxaliplatin combination ( “GROC-Rev”) in 33 patients. We observed a response rate of 61% (39% complete response rate) and 3-year overall survival of 47%, superior to previous experience. GROC-Rev is a new salvage regimen with encouraging results.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research

Related Links:

In this study, we used large-scale electronic health records data from multiple linked UK databases to address these evidence gaps.MethodsFor this population-based cohort study, we used linked primary care, hospital, and cancer registry data from the UK Clinical Practice Research Datalink to identify cohorts of survivors of the 20 most common cancers who were 18 years or older and alive 12 months after diagnosis and controls without history of cancer, matched for age, sex, and general practice. We compared risks for a range of cardiovascular disease outcomes using crude and adjusted Cox models. We fitted interactions to in...
Source: The Lancet - Category: General Medicine Source Type: research
The objective is, therefore, to examine the relation between co-morbid CVD at cancer diagnosis and HRQoL among cancer survivors diagnosed with colorectal, thyroid, prostate, endometrium, ovarian cancer, melanoma, (non-)Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), or multiple myeloma (MM) in an exploratory population-based cross-sectional study. Material and methods: Analyses were performed on combined data sets from the PROFILES and Netherlands Cancer Registry (NCR). Data on co-morbid CVD at cancer diagnosis was extracted from the NCR. HRQoL was measured via PROFILES at a median of 4.6 years after cancer di...
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
Publication date: Available online 30 May 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Katharina Kriegsmann, Julia S. Klee, Manfred Hensel, Eike C. Buss, Mark Kriegsmann, Martin Cremer, Anthony D. Ho, Gerlinde Egerer, Patrick Wuchter, Mathias Witzens-HarigAbstractBackgroundMalignant lymphoma is still the leading cause of death among AIDS-related diseases.Patients and MethodsWe performed a retrospective analysis of 50 HIV-positive lymphoma patients. The median interval between HIV and malignant lymphoma diagnosis was 4 years. Eight patients (16%) had Hodgkin lymphoma and 42 (84%) non-Hodgkin lymphoma. Among ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
The objective of this study was to develop a population-pharmacokinetic model of durvalumab in patients with various hematologic malignancies and to investigate the effects of demographic and disease factors on the pharmacokinetics in this population.MethodsA total of 1812 concentrations from 267 patients with myelodysplastic syndromes, acute myeloid leukemia, multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma were included in the analysis.ResultsThe pharmacokinetics of durvalumab was adequately described by a two-compartment model with first-order elimination. A decrease in durvalumab clearance over time was main...
Source: Clinical Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research
The objective of this study was to develop a population-pharmacokinetic model of durvalumab in patients with various hematologic malignancies and to investigate the effects of demographic and disease factors on the pharmacokinetics in this population. METHODS: A total of 1812 concentrations from 267 patients with myelodysplastic syndromes, acute myeloid leukemia, multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma were included in the analysis. RESULTS: The pharmacokinetics of durvalumab was adequately described by a two-compartment model with first-order elimination. A decrease in durvalumab clearance ov...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Clin Pharmacokinet Source Type: research
Publication date: Available online 17 July 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Fernando Cabanillas, Noridza Rivera, Mirelis Acosta, Wandaly Pardo, Pedro Solivan, Caroline Rivera, Idalia LiboyAbstractBackgroundOur objective was to evaluate the impact of lenalidomide in patients with aggressive lymphoma who attained
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Abstract Chimeric antigen receptor (CAR) modified T-cell therapy, a unique platform technology highlighting precision medicine through utilization of molecular biology and cell-based therapeutics has shown unprecedented rates in patients with hematological malignancies such as acute lymphocyte leukemia, non-Hodgkin's lymphoma and multiple myeloma (MM). With the approval of CD19-targeted CAR T-cells by the Food and Drug Administration in acute lymphoblastic leukemia (ALL) and NHL, this technology is positioned for aggressive expansion to combination therapeutic opportunities and proof of principle towards utility i...
Source: Oncology - Category: Cancer & Oncology Authors: Tags: Oncology Source Type: research
Publication date: Available online 26 June 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Amy A. Ayers, Lin Lyu, Kaylin Dance, Kevin C. Ward, Christopher R. Flowers, Jean L. Koff, Lauren E. McCulloughAbstractBackgroundRacial disparities in non-Hodgkin lymphoma (NHL) are not well elucidated for specific catchment areas, which can influence outcomes. Leveraging regional data from a population-based cancer registry may provide unique opportunities to quantify NHL disparities.MethodsUsing Surveillance, Epidemiology and End Results (SEER) data for NHL cases diagnosed in Georgia from 2001 to 2015, we examined NHL i...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion : Venetoclax is a mild and efficient drug in treating advanced hematological malignancy which is specially fit for the CLL patients with del[17p], and AEs are well-tolerable. Few tumor lysis syndrome (TLS) occurred after taking the drugs. The AEs aroused by venetovlax and combination are well-tolerable. Therefore, the use of venetoclax monotherapy or its combination with other therapies is desirable in hematological malignancy.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 29 May 2019Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Pooja Advani, Aneel Paulus, Sikander AilawadhiAbstractWaldenström’s macroglobulinemia (WM) is a rare, incurable hematologic disorder with a relatively indolent course in a majority of the patients. Despite this, a significant proportion of patients require treatment because of hypersecretion of immunoglobulin M and the invasion of bone marrow and peripheral organs by neoplastic lymphoplasmacytic lymphoma cells. Historically, there has been a dearth of research and therapeutic advancements in the field of WM,...
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research
More News: Eloxatin | Hematology | Leukemia | Lymphoma | Myeloma | Non-Hodgkin's Lymphoma | Revlimid | Rituxan | Study